Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Sep 17, 2026
TickeronGET DAILY SIGNALS
Why Is Tempus AI (TEM) Stock Up +10.46% Today?

Why Is Tempus AI (TEM) Stock Up +10.46% Today?

Key Takeaways

  • TEM shares jumped roughly 10.46% on September 17, 2026, climbing from a prior close of $69.97 to about $77.29.
  • The primary catalyst was an analyst upgrade from Piper Sandler, which lifted TEM to Overweight and raised its price target from $56 to $76.
  • Supportive drivers included a $9.5 million federal grant tied to cardiology AI development and renewed enthusiasm around its pending acquisition of PSNL (Personalis).
  • The move tracked a broad rally in AI and healthcare-technology names, adding momentum to the stock's multi-week advance.
  • Traders are watching integration milestones for the Personalis deal, oncology-testing adoption, and the company's next earnings report.

Opening Summary

TEM, the ticker for Tempus AI, Inc., is a healthcare-technology company that applies artificial intelligence and machine learning to precision medicine, combining molecular testing with clinical data to help physicians make more informed treatment decisions. On September 17, 2026, the stock surged approximately 10.46%, rising from a prior session close of $69.97 to around $77.29 in intraday trading. The move, confirmed as a significant gain, was driven primarily by an analyst upgrade alongside positive sector sentiment and company-specific developments in oncology diagnostics and cardiology AI.

Analyst Upgrade

The clearest catalyst behind the rally was an upgrade from Piper Sandler, which moved its rating on TEM from Neutral to Overweight and raised its price target to $76 from $56. The analyst cited three emerging growth drivers: the pending acquisition of PSNL (Personalis), favorable results from the INTerpath-001 study, and FDA clearance of the xT CDx test. The shift in stance signaled that the firm now sees tangible fundamental progress supporting the valuation, rather than enthusiasm for artificial intelligence alone, prompting investors to reprice the stock higher.

Personalis Acquisition and Oncology Momentum

The planned acquisition of PSNL (Personalis) remained a central focus. The transaction gives Tempus access to a tumor-informed minimal residual disease (MRD) platform, a capability analysts view as a distinctive asset in oncology diagnostics. Favorable results from the INTerpath-001 study strengthened the strategic case for the deal, while the FDA's clearance of the tumor-only xT CDx test removed a key regulatory hurdle and supported the company's path toward unified ADLT pricing across its diagnostic portfolio. The combination of these milestones reinforced confidence in TEM's longer-term growth trajectory.

Federal Grant and Broader AI Sentiment

Additional support came from news that the company secured a roughly $9.5 million federal grant tied to cardiology AI development, underscoring the expanding application of its platform beyond oncology. The stock also benefited from a wider rally in AI-related equities, with healthcare-AI names trading higher alongside strength in the technology sector. This favorable backdrop amplified the move, as investors rotated toward companies perceived to be translating AI investments into commercial traction.

Market Context and Trading Activity

Trading volume in TEM was elevated relative to its average, reflecting heightened investor interest following the upgrade and related announcements. The advance extended a multi-week uptrend that had already carried the shares well above their 50-day and 200-day moving averages. The gain outpaced the broader market, indicating that company-specific catalysts, rather than a simple index move, drove the outperformance even as the broader AI and healthcare-technology complex traded firmly.

What Comes Next for TEM

Looking ahead, investors will monitor progress on closing the Personalis acquisition, which is expected to complete in late 2026 or early 2027, as well as the integration of its MRD capabilities. Continued adoption of the company's oncology diagnostics and data-licensing businesses, along with execution on recent federal funding, will be closely watched. The company's next earnings report is scheduled for early November, offering the next major checkpoint on revenue growth and profitability. Risks include the company's history of net losses, insider selling, and the high volatility typical of AI-focused healthcare names.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and the symbols they trade. Only the top performers are featured in this section. Explore the Trending AI Robots to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TEM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


TEM in downward trend: price dove below 50-day moving average on November 13, 2026

TEM moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend. In 19 of 20 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEM as a result. In 30 of 37 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for TEM turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 23 similar instances when the indicator turned negative. In 17 of the 23 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

The 10-day moving average for TEM crossed bearishly below the 50-day moving average on November 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for TEM entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for TEM's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +19.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 117 of 132 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

TEM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (31.032) is slightly higher than the industry average of (4.523). TEM has a moderately low P/E Ratio (-52.812) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.105).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
600 West Chicago Avenue
Phone
+1 800 976-5448
Employees
3800
Web
https://www.tempus.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.